3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
First received: June 6, 2001
Last updated: July 17, 2013
Last verified: December 2007

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining 3-AP, cisplatin, and paclitaxel in treating patients who have advanced or metastatic cancer.

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
Drug: cisplatin
Drug: paclitaxel
Drug: triapine
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: December 2000
Study Completion Date: January 2008
Detailed Description:


  • Determine the safety and tolerability of 3-AP, cisplatin, and paclitaxel in patients with advanced or metastatic cancer.
  • Determine the toxic effects of this regimen in these patients.
  • Determine the maximum tolerated dose and recommended phase II dose of this regimen in these patients.
  • Determine the pharmacokinetic parameters of this regimen in these patients.
  • Determine the tumor response in patients treated with this regimen.

OUTLINE: This is a dose-escalation study.

Patients receive 3-AP IV continuously over 96 hours on days 1-4 and paclitaxel IV over 3 hours followed by cisplatin IV over 1 hour on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 1 additional course of therapy after documented CR. Patients with partial response or stable disease may receive therapy for up to 6 months.

Cohorts of 1-6 patients receive escalating doses of 3-AP, paclitaxel, and cisplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


  • Histologically confirmed progressive advanced or metastatic cancer

    • Failed 1 or more prior standard therapies for disease OR
    • Unlikely to respond to any currently available therapies
  • Measurable or evaluable disease
  • No active CNS metastases

    • Previously treated CNS metastases allowed if no evidence of new CNS metastases and stable for at least 2 months



  • 18 and over

Performance status:

  • ECOG 0-1

Life expectancy:

  • More than 3 months


  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 10 g/dL (transfusion allowed)
  • No active bleeding or coagulation disorder (occult blood for gastrointestinal cancer allowed)


  • Bilirubin no greater than 1.5 mg/dL
  • ALT/AST no greater than 3 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 3 times ULN (5 times ULN if liver metastases present)
  • Albumin at least 3.0 g/dL
  • PT/PTT no greater than 1.5 times ULN


  • Creatinine no greater than 1.5 mg/dL


  • No active heart disease
  • No myocardial infarction within the past 3 months
  • No symptomatic coronary artery disease, heart block, or uncontrolled congestive heart failure


  • No moderate to severe compromise in pulmonary function


  • No mental deficits and/or psychiatric history that would preclude study
  • No active infection
  • No pre-existing severe hearing impairment
  • No pre-existing grade 2 or greater neuropathy
  • No prior severe allergic reaction to study drugs
  • No other life-threatening illness
  • No chronic toxic effects from prior chemotherapy greater than grade I
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 18 months after study participation


Biologic therapy:

  • Concurrent hematopoietic growth factors allowed except if used prophylactically during first course of study therapy


  • More than 3 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered
  • More than 6 months since prior combination cisplatin and paclitaxel
  • Prior cisplatin or paclitaxel as single agents allowed
  • Prior 3-AP allowed

Endocrine therapy:

  • Not specified


  • More than 3 weeks since prior radiotherapy and recovered
  • Concurrent radiotherapy to a single site of progressive disease allowed if site requires treatment within the first course of study therapy


  • Not specified


  • More than 3 weeks since any therapy for malignancy and recovered
  • No other concurrent investigational drugs without consent of sponsor
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00016874

United States, New York
Albert Einstein Comprehensive Cancer Center
Bronx, New York, United States, 10461
New York Presbyterian Hospital - Cornell Campus
New York, New York, United States, 10021
Sponsors and Collaborators
Vion Pharmaceuticals
Study Chair: Mario Sznol, MD Vion Pharmaceuticals
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00016874     History of Changes
Other Study ID Numbers: VION-CLI-015, CDR0000068591, AECM-1200012380, NCI-V01-1658
Study First Received: June 6, 2001
Last Updated: July 17, 2013
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic

ClinicalTrials.gov processed this record on April 16, 2014